CytomX Therapeutics (CTMX) Enterprise Value (2014 - 2026)

CytomX Therapeutics has reported Enterprise Value for 13 years, with the latest figure at -$346.7 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 334.0% year-over-year to -$346.7 million; the trailing twelve-month figure through Mar 2026 stood at -$346.7 million (down 334.0% YoY), and the FY2025 full-year result was -$137.1 million, down 36.2% from the prior year.
• Enterprise Value for Q1 2026 stood at -$346.7 million, down from -$137.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$79.9 million in Q1 2025, with the low at -$346.7 million in Q1 2026.
• Historically, Enterprise Value has averaged -$176.7 million across 5 years, with a median of -$174.5 million in 2023.
• Annual changes were most pronounced in 2025 — Enterprise Value soared 46.84% — and 2026, when it sank 334.0%.
• CytomX Therapeutics' Enterprise Value stood at -$193.6 million in 2022, then increased by 9.88% to -$174.5 million in 2023, then soared by 42.34% to -$100.6 million in 2024, then slumped by 36.2% to -$137.1 million in 2025, then plunged by 152.97% to -$346.7 million in 2026.
• The last three Enterprise Value figures came in at -$346.7 million (Q1 2026), -$137.1 million (Q4 2025), and -$143.6 million (Q3 2025), per Business Quant data.